Background
==========

Colorectal cancer is usually an adenocarcinoma that arises from the colon or rectum. It is the second and the third most common cancer in women and men in the world, respectively \[[@b1-medscimonit-23-3026]\]. Colorectal cancer is also the fourth leading cause of cancer-related death worldwide, with an estimated 694 000 (8.5%) deaths in 2012 \[[@b2-medscimonit-23-3026],[@b3-medscimonit-23-3026]\]. Surgery is the main treatment for colorectal cancer, but post-operative recurrence and metastasis lead to a poor prognosis for patients with this disease \[[@b4-medscimonit-23-3026]\]. Anatomic and pathological stages are still the most accurate predictors of colorectal cancer prognosis, and once tumor cells have spread, the long-term prognosis is poor because no curative treatments are available. Therefore, novel molecular biomarkers for colorectal cancer are needed for accurate prediction.

Tumorigenesis in humans is a multistep process, reflecting an accumulation of genetic changes that lead normal cells to transform into cancer cells \[[@b5-medscimonit-23-3026]\]. The causes of genetic alterations are multifactorial, with exogenous and endogenous factors known to induce a variety of genetic alterations, including DNA methylation, insertions, base substitutions, and deletions \[[@b6-medscimonit-23-3026],[@b7-medscimonit-23-3026]\]. The abnormal methylation of tumor suppressor gene promoter regions can increase the degree of chromatin spiral, and can lead to gene transcription inhibition, which is closely related to tumorigenesis. Colorectal cancer is one of the best characterized tumors with regard to the genetic mechanisms involved in its development \[[@b8-medscimonit-23-3026]--[@b12-medscimonit-23-3026]\]. However, the clinical significance of these genetic alterations is still unclear. Human mutL homolog 1, known as *hMLH1*, can mediate protein-protein interactions during mismatch recognition, strand discrimination, and strand removal. It is a human gene located on chromosome 3 and is commonly associated with hereditary nonpolyposis colorectal cancer. Aberrant hypermethylation of CpG islands in *hMLH1* promoter regions is known to play an important role in the tumorigenesis of human colorectal cancer; its epigenetic alterations may affect DNA stability, such as chromosomal instability and microsatellite instability (MSI) \[[@b13-medscimonit-23-3026]\]. About 15% of colorectal cancers show a high level of MSI, reflecting dysfunction of the post-replicative DNA mismatch repair system, mainly through the CpG methylation-mediated silencing of the *hMLH1* gene \[[@b7-medscimonit-23-3026],[@b14-medscimonit-23-3026]--[@b16-medscimonit-23-3026]\].

This systematic literature review aimed to quantify the impacts of *hMLH1* hypermethylation on the risk of colorectal cancer and MSI based on the above results and through selecting a large number of published articles on colorectal cancer.

Material and Methods
====================

Literature search
-----------------

This pooled study involved searching a range of computerized databases, including PubMed, Cochrane Library, Web of Science, and Google Scholar for articles published in English before March 2015. The study used a subject and text word strategy with "colorectal cancer or colon cancer or colorectal carcinoma" and "hMLH1 or human mutL homolog 1" and "methylation or hypermethylation or epigenetic".

Inclusion and exclusion criteria
--------------------------------

The included articles had to meet the following criteria: (1) original study; (2) the diagnosis of colorectal cancer was based on clinical diagnosis through histopathology; (3) studies with a case--control design and available frequency of the *hMLH1* promoter methylation; (4) only the data from articles with full text in English were included in the analysis. The article title, author names, year published, research institutions, and procedures for enrolling participants were checked to avoid duplication of data. If several publications were reported with the same population data, only the most complete study with more information was included. For case group and control group, we defined the number of *hMLH1* hypermethylation of colorectal cancer tissues/blood (or high-level MSI in colorectal cancer) as case groups and the number of *hMLH1* hypermethylation of normal (corresponding adjacent non-cancer tissues or healthy tissues/blood from a healthy person) (or microsatellite stability in colorectal cancer) as control groups in individuals. Exclusion criteria were: (1) studies not focused on the association of colorectal cancer or *hMLH1*; (2)*hMLH1* methylation conducted only in the cell lines; (3) no raw data available or cannot retrieve any raw data; (4) conference papers, case reports, letters, or reviews papers.

Data extraction
---------------

Data were extracted from each study by 2 independent reviewers (HF Zhang and YW Lu) using the selection standards described above. Decisions were made and disagreements about study selection were resolved by discussing with ZR Xie and KH Wang. The following information was extracted from the studies: the first author's last name, publication year, original country of patients in the subjects, sex, age, and the number of *hMLH1* hypermethylation of cases and controls in individuals.

Statistical analysis
--------------------

This meta-analysis used pooled odds ratio (OR) with its 95% confidence interval (CI) to measure the strength of the association between the *hMLH1* promoter methylation and colorectal cancer. The significance of the pooled OR was determined by *p*\<0.05, which was considered as statistically significant. *I*^2^ statistic with values over 50% and chi-squared test with *p*≤0.1 were considered to show strong heterogeneity between studies \[[@b17-medscimonit-23-3026]\]. According to the heterogeneity statistic *I*^2^, the data were pooled using the random-effects model when *I*^2^\>50% and *p*≤0.1, or the fixed-effects model when *I*^2^\<50% \[[@b18-medscimonit-23-3026]\]. Subgroup analyses were performed according to different ethnic groups and the specimen source in consideration of the source of heterogeneity. Tau-squared (χ^2^) was used to determine how much heterogeneity was explained by subgroup differences. To assess the contributions of single studies to the final results, sensitivity analyses were performed. Begg's test and Egger's test were carried out to examine whether the results of a meta-analysis had been affected by publication bias and funnel plot asymmetry \[[@b19-medscimonit-23-3026]\]. All statistical analyses were performed using *R* Software (*R* version 3.1.2) including meta packages.

Results
=======

Eligible sudies and study characteristics
-----------------------------------------

After being selected in accordance with the inclusion criteria, 45 studies met the standard, as shown in [Figure 1A](#f1-medscimonit-23-3026){ref-type="fig"} \[[@b20-medscimonit-23-3026]--[@b66-medscimonit-23-3026]\]. The characteristics of the 45 retained studies are listed in [Tables 1](#t1-medscimonit-23-3026){ref-type="table"} and [2](#t2-medscimonit-23-3026){ref-type="table"}. The studies included were published between 2003 and 2014 ([Figure 1B](#f1-medscimonit-23-3026){ref-type="fig"}) and were conducted in 18 countries ([Figure 1C](#f1-medscimonit-23-3026){ref-type="fig"}). A total of 33.47% of colorectal cancer patients had the methylated *hMLH1* allele, with a frequency ranging from 3.73% to 100% in individual trials. Among the 45 studies, 13 focused on the MSI, which were divided into MSI-H (high-level MSI) and MSS (microsatellite stability).

Meta-analysis
-------------

The main results of this meta-analysis and the heterogeneity test are shown in [Figures 2](#f2-medscimonit-23-3026){ref-type="fig"}[](#f3-medscimonit-23-3026){ref-type="fig"}--[4](#f4-medscimonit-23-3026){ref-type="fig"}. Significant heterogeneity was observed in overall and stratified analyses; the pooled OR for colorectal cancer risk was calculated by fixed-effect model and random-effects model. The combined results based on 45 studies show that the *hMLH1* promoter hypermethylation was significantly associated with the increased risk of colorectal cancer using the fixed-effects model (OR=8.3820; 95%CI, 6.9202\~10.1527; z=21.7431;*P*\<0.0001) and random-effects model (OR=10.0963; 95%CI, 6.1919\~16.4626; z=9.2688; *P*\<0.0001). For heterogeneity, pooled tau^2^ was 1.7063 and I^2^ was 74.6%. The OR showed that colorectal cancer patients have a 10.0963-fold higher risk for *hMLH1* hypermethylation compared with that in adjacent tissues and normal blood by the random-effects model, suggesting a statistically significant increase in likelihood of methylation in colorectal cancer compared to adjacent tissues and normal blood.

The relationship between subgroup and *hMLH1* promoter hypermethylation among colorectal cancer cases were also conducted. For the subgroup analysis of ethnicity by random-effects model, the OR for the Asian subgroup was 16.83 (95% CI, 10.08\~28.09) from 19 studies, the Caucasian subgroup was 6.60 (95% CI, 2.26\~19.28) from 12 studies, the Indian subgroup was 8.71 (95% CI, 1.85\~41.01) from 4 studies, the African subgroup was 3.31 (95% CI, 1.50\~7.34) from 2 studies, and the mixed-race subgroup was 12.42 (95% CI, 3.12\~49.49) from 8 studies (all *P*\<0.0001) ([Figure 3A](#f3-medscimonit-23-3026){ref-type="fig"}). In the subgroup analysis of sample source, the OR in the tissues was 11.95 (95% CI, 7.26\~19.68; *P*\<0.0001) and the OR in the blood was 3.15 (95% CI, 0.71--13.93; *P*\<0.0001) ([Figure 3B](#f3-medscimonit-23-3026){ref-type="fig"}).

For the relationship between *hMHL1* gene promoter and MSI, 13 articles were analyzed showing MSI-H had a 6.09- or 6.48-fold higher significance than MSS by fixed- or random-effects models ([Figure 4](#f4-medscimonit-23-3026){ref-type="fig"}). Hypermethylation of *hMLH1* gene promoter was the main mechanism underlying the pathogenesis of MSI colorectal cancer \[[@b28-medscimonit-23-3026],[@b62-medscimonit-23-3026]\] and this meta-analysis identified the same result.

Publication bias and sensitivity analysis
-----------------------------------------

To ensure the quality of this study, a Begg's funnel plot and Egger's tests were performed to eliminate the publication bias of included studies. Visual assessment of the Begg's test did not reveal any evidence of obvious asymmetry in all data analysis (*t*=−0.9897, *P*=0.3279). Meanwhile, Egger's test also provided statistical evidence of funnel plot symmetry and detected little evidence of publication bias (t=3.9443, *P*=0.0002907). Therefore, there was little publication bias for the 45 studies ([Figure 5A](#f5-medscimonit-23-3026){ref-type="fig"}).

Sensitivity analyses were conducted to determine whether any single study of this meta-analysis affected the final results. According to sensitivity analysis with the 45 studies, the OR ranged from 9.1372 (95% CI, 5.7054\~14.6331) to 10.8803 (95% CI, 6.8569\~17.2643) by omitting a single study under the random-effects model, which suggested that there was no change in the OR or the 95% CI after each deletion ([Figure 5B](#f5-medscimonit-23-3026){ref-type="fig"}).

Discussion
==========

Colorectal cancer is a major cause of cancer-associated morbidity and mortality worldwide. The epidemiology of colorectal cancer has been studied by researchers, but the results have been insufficient. This meta-analysis retrospectively included 45 studies, aiming to investigate whether promoter DNA methylation of the *hMHL1* gene has an effect on the risk of colorectal cancer. The meta-analysis results revealed that the frequency of *hMHL1* gene promoter hypermethylation in colorectal cancer tissues/blood was significantly higher than that in normal tissues/blood, suggesting that *hMHL1* gene promoter hypermethylation may be implicated in the development and progression of colorectal cancer. Although the exact role of methylation status of the *hMHL1* gene in colorectal cancer carcinogenesis is still indistinct, CpG island hypermethylation in the *hMHL1* promoter region maybe lead to transcriptional silencing, and thus inhibit its function to the DNA mismatch repair pathway, resulting in the development of colorectal cancer \[[@b67-medscimonit-23-3026]\]. The results of subgroup analysis based on ethnicity demonstrated that *hMHL1* gene promoter hypermethylation was closely associated with the risk of colorectal cancer among Asians, Caucasians, Indians, Africans and mixed-race people, revealing that there was no ethnic difference in the effects of *hMHL1* gene promoter hypermethylation on colorectal cancer susceptibility.

The development of human cancer is associated with genomic instability, which causes the accumulation of genetic changes that eventually result in the conversion of normal cells to malignant phenotypes. The human DNA repair system plays an important role in reducing mutations and maintaining genomic stability. The 1 mismatch of repair genes, *hMLH1*, is an integral component of the DNA mismatch repair pathway. Defective DNA mismatch repair is most commonly associated with the functional loss of *hMLH1* genes and results in the methylator phenotypes characterized by MSI in colorectal cancer. This meta-analysis result of 13 articles found that MSI-H have a higher frequency of *hMHL1* gene promoter hypermethylation than MSS by fixed- and random-effects models, indicating a significant relationship between *hMHL1* gene promoter hypermethylation and MSI in colorectal cancer.

There also existed 3 limitations in this meta-analysis that should be interpreted. A first potential limitation stemmed from the small numbers of studies and wide standard deviations, thereby limiting confidence in drawing conclusions. Secondly, the meta-analysis is a retrospective study that may lead to subject selection bias, thereby influencing the reliability of the meta-analysis results. Thirdly, the results this meta-analysis have insufficient statistical power to assess the correlations between *hMHL1* gene promoter hypermethylation and the development and progression of colorectal cancer. Although this study has the above limitations, this meta-analysis has a high value for the risk of colorectal cancer. Furthermore, additional studies with a larger sample size are still required to provide a more representative and convincing statistical analysis.

Conclusions
===========

This meta-analysis showed a positive association between *hMHL1* gene promoter hypermethylation and colorectal cancer risk. Thus, *hMHL1* gene promoter hypermethylation might be a valuable diagnostic biomarker for the early detection of colorectal cancer.
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![(**A--C**)Flow chart shows study selection procedure and the distribution of the number of topic-related articles in the electronic database during the last decade.](medscimonit-23-3026-g001){#f1-medscimonit-23-3026}

![The combined estimates for the association between *hMHL1* gene promoter hypermethylation and colorectal cancer with forest plot.](medscimonit-23-3026-g002){#f2-medscimonit-23-3026}

![Subgroup meta-analysis for the relationship between *hMHL1* gene promoter hypermethylation and colorectal cancer risk. (**A**) Ethnicity was categorized as "Asian", "Caucasian", "India's race", "African descent" and "Mixed-Race". Samples of studies from the USA and Brazil are "Mixed-Race" ethnicity, and Iran and India are Indian ethnicity. (**B**) Subgroup meta-analysis based on different samples by random-effects model.](medscimonit-23-3026-g003){#f3-medscimonit-23-3026}

![Forest plots for the relationship between *hMHL1* gene promoter hypermethylation and MSI in colorectal cancer.](medscimonit-23-3026-g004){#f4-medscimonit-23-3026}

![Begg's funnel plot of publication biases and sensitivity analysis on the relationship between *hMHL1* gene promoter hypermethylation and colorectal cancer susceptibility. (**A**) The natural logarithm of odds ratio (OR) and its standard error were used in the funnel plot. The circles correspond to the log OR from individual trials, and the diagonal lines show the expected 95% confidence interval (CI) around the summary estimate. (**B**) Sensitivity analysis of the summary odds ratio coefficients on the relationship between *hMHL1* promoter methylation and the colorectal cancer patients.](medscimonit-23-3026-g005){#f5-medscimonit-23-3026}

###### 

Main characteristics of the studies included in the meta-analysis.

  Author                      Year   Country        Method   Sample   Median age (year)   TNM. stage   Male/f emale   Case   Control        
  --------------------------- ------ -------------- -------- -------- ------------------- ------------ -------------- ------ --------- ---- -----
  Morimoto et al.             2014   Japan          MSP      Tissue   60.5                NA           62/43          41     65        0    5
  Malhotra et al.             2014   India          MSP      Tissue   56                  I--IV        10/20          15     15        3    27
  Kanth et al.                2014   India          MSP      Tissue   40                  I--IV        61/30          44     47        12   79
  Coppedè et al.              2014   Italy          MS-HRM   Tissue   71.07               I--IV        61/46          13     94        1    79
  Vergouwe et al.             2013   South Africa   MSP      Tissue   58.5                I--IV        34/44          45     33        5    12
  Huang et al.                2012   China          MSP      Tissue   50                  I--IV        17/13          6      24        0    30
  Maeda et al.                2011   Japan          Chip     Tissue   60.9                I--IV        27/39          30     33        0    24
  Lee et al.                  2011   Korea          MSP      Tissue   63.4                I--IV        77/35          28     108       0    112
  Kim et al.                  2011   Korea          MSP      Blood    61.78               I--IV        35/32          15     36        0    51
  Auclair et al.              2011   France         MSP      Blood    50                  NA           NA             55     55        18   5
  Aoyagi et al.               2011   Japan          QMSP     Tissue   64.5                III--IV      86/48          30     104       0    134
  Ahn et al.                  2011   Korea          MSP      Tissue   61                  III          93/76          6      155       0    161
  Psofaki et al.              2010   Greece         MSP      Tissue   62.5                I--IV        44/35          36     43        2    18
  Miladi-Abdennadher et al.   2011   Tunisian       MSP      Tissue   62.9                I--IV        46/26          38     34        5    15
  Mirchev et al.              2010   Germany        MSP      Tissue   73.8                I--IV        67/83          150    0         39   111
  Hiraki et al.               2010   Japan          QMSP     Tissue   65.5                II--IV       10/17          4      23        1    26
  Menigatti et al.            2009   Switzerland    QMSP     Tissue   65                  I--IV        53/47          20     213       6    94
  Lee et al.                  2009   Korea          MSP      Blood    61                  I--II        139/104        51     192       4    144
  Kawaguchi et al.            2009   Japan          MSP      Tissue   57.7                I--III       NA             17     27        0    44
  Ramirez et al.              2008   Spain          MSP      Tissue   67                  I--IV        53/29          22     60        9    73
  Nagasaka et al.             2008   Japan          COBRA    Tissue   65                  I--IV        157/86         15     14        39   168
  Mokarram et al.             2008   Iran           MSP      Blood    60.42               I--IV        90/61          20     131       8    73
  Kim et al.                  2008   Korea          MSP      Tissue   60                  I--III       15/10          5      20        0    25
  Kakar et al.                2008   USA            MSP      Tissue   NA                  NA           NA             2      28        0    32
  Ide et al.                  2008   Japan          MSP      Tissue   60                  I--IV        60/34          87     7         18   76
  Fujiwara et al.             2008   Japan          COBRA    Tissue   55                  NA           34/23          40     17        0    20
  Brim et al.                 2008   Iran           MSP      Tissue   65.7                I--IV        39/56          66     4         5    30
  Noda et al.                 2007   Japan          MSP      Tissue   65                  I--IV        14/16          10     20        2    14
  Leung et al.                2007   China          MSP      Tissue   69                  NA           NA             5      15        1    29
  Greenspan et al.            2007   USA            MSP      Tissue   60                  NA           NA             8      31        0    39
  Zhang et al.                2006   China          MSP      Tissue   62                  I--IV        9/11           8      12        0    20
  Ye et al.                   2006   USA            MSP      Tissue   57.5                NA           71/26          12     85        11   83
  Wallner et al.              2006   Germany        QMSP     Tissue   67                  I--IV        26/12          19     19        0    20
  O'Brien et al.              2006   USA            MSP      Tissue   NA                  NA           NA             221    239       9    56
  Fox et al.                  2006   Ireland        MSP      Tissue   69                  I--IV        52/58          13     97        3    107
  Derks et al.                2006   Netherlands    MSP      Tissue   67                  I--IV        NA             13     5         9    9
  Leung et al.                2005   China          MSP      Blood    57                  I--IV        18/31          19     30        4    37
  Ashktorab et al.            2005   USA            MSP      Tissue   68                  I--IV        15/19          29     5         0    34
  Anacleto et al.             2005   Brazil         MMSP     Tissue   NA                  NA           NA             16     82        0    30
  Anacleto et al.             2005   Brazil         MSP      Tissue   NA                  NA           NA             19     90        0    30
  Xu et al.                   2004   China          MSP      Tissue   60                  I--IV        37/28          12     53        1    5
  Kim et al.                  2004   Korea          MSP      Tissue   56                  I--IV        71/63          30     104       0    64
  Arnold et al.               2004   USA            MSP      Tissue   NA                  NA           70/79          46     127       0    173
  Lee et al.                  2004   Korea          MSP      Tissue   58                  I--IV        70/79          30     119       0    24
  Strazzullo et al.           2003   Italy          MSP      Tissue   NA                  NA           NA             8      34        0    42
  Roh et al.                  2003   Korea          MSP      Tissue   25                  I--IV        15/6           3      18        0    21
  Ricciardiello et al.        2003   Italy          MSP      Tissue   62                  NA           40/30          9      61        0    70
  Kamory et al.               2003   Hungary        MSP      Tissue   65                  NA           19/18          7      30        0    37

MSP -- methylation specific polymerase chain reaction; QMSP -- quantitative methylation specific polymerase chain reaction; MS-HRM -- Methylation sensitive-high resolution melting; COBRA -- Combined Bisulfite Restriction Assays; M -- the number of patients with methylation; U -- the number of patients with unmethylation; NA -- not available.

###### 

The article features of the relationship between *hMHL1* gene promoter hypermethylation and MSI in colorectal cancer.

  Author                 Year   Country   Method   Sample   Median age (year)   TNM. stage   Male/female   MSI-H   MSS        
  ---------------------- ------ --------- -------- -------- ------------------- ------------ ------------- ------- ----- ---- -----
  Kanth et al.           2014   India     MSP      Tissue   40                  I--IV        61/30         27      17    11   36
  Maeda et al.           2011   Japan     Chip     Tissue   60.9                I--IV        27/39         12      12    0    42
  Kawaguchi et al.       2009   Japan     MSP      Tissue   57.7                I--III       NA            10      7     7    20
  Nagasaka et al.        2008   Japan     COBRA    Tissue   65                  I--IV        157/86        15      21    0    207
  Kim et al.             2008   Korea     MSP      Tissue   60                  I--III       15/10         5       4     3    13
  Fujiwara et al.        2008   Japan     COBRA    Tissue   55                  NA           34/23         13      10    3    30
  Brim et al.            2008   Iranian   MSP      Tissue   65.7                I--IV        39/56         48      2     18   2
  Greenspan et al.       2007   USA       MSP      Tissue   60                  NA           NA            2       9     7    14
  Fox et al.             2006   Ireland   MSP      Tissue   69                  I--IV        52/58         8       2     5    95
  Ashktorab et al.       2005   USA       MSP      Tissue   68                  I--IV        15/19         16      3     13   2
  Kim et al.             2004   Korea     MSP      Tissue   56                  I--IV        71/63         10      13    20   91
  Arnold et al.          2004   USA       MSP      Tissue   NA                  NA           70/79         19      8     27   119
  Roh et al.             2003   Korea     MSP      Tissue   25                  I--IV        15/6          3       9     0    9
  Ricciardiello et al.   2003   Italy     MSP      Tissue   62                  NA           40/30         6       3     0    61

MSP -- methylation specific polymerase chain reaction; COBRA -- Combined Bisulfite Restriction Assays; M -- the number of patients with methylation; U -- the number of patients with unmethylation; MSI-H -- high-level MSI; MSS -- microsatellite stability; NA -- not available.
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